Moderna ($MRNA) stock jumped 17% on Thursday, fueled by speculation of potential buyout talks amid concerns over declining ...

Moderna (NASDAQ:MRNA) stock surged as much as 12% Thursday following a STAT News report that the COVID-19 vaccine maker has been in discussions with at least one large pharmaceutical company about "a ...

The market expects Moderna (MRNA) to deliver a year-over-year decline in earnings on lower revenues when it reports results ...

Moderna (MRNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...

The biotech's innovative qualities will come in handy. Long gone are the days when Moderna ( MRNA 2.66%) would generate over $18 billion in annual sales from its COVID-19 vaccine. Over the past couple ...

The vaccine, known as mRNA-1647, showed disappointing efficacy against primary CMV infection in healthy women, ranging from just 6% to 23% depending on the case definition used. As a result, Moderna ...

Moderna ends its CMV vaccine program after a Phase 3 trial failed to meet efficacy goals, but maintains its 2028 breakeven ...

Shares of Moderna MRNA were up 4% yesterday after the company announced positive preliminary immunogenicity data from an ongoing phase IV study, which evaluated the updated version of its COVID-19 ...

In the latest trading session, Moderna (MRNA) closed at $25.51, marking a +2.03% move from the previous day. This change outpaced the S&P 500's 0.48% gain on the day. On the other hand, the Dow ...

In a mixed interim data drop, Arcturus Therapeutics has revealed a lack of efficacy for its investigational inhaled mRNA ...